WASHINGTON — National Institutes of Health Director Jay Bhattacharya will elevate the interim head of the National Institute of Allergy and Infectious Diseases to become its new director on Monday, in a pivot away from biodefense research and back to immunology basics.
Bhattacharya is appointing John Powers — a 20-year veteran of NIAID and its fourth director in the last four years — to usher in a new era at the agency that will end what he bluntly dubbed the “mad science experiments” of ex-director Anthony Fauci.
Fauci ran NIAID for 40 years and had great success in developing life-saving treatments for HIV as well as running the biodefense and emerging infectious disease research that soon took up the largest portion of its annual budget.
“There’s a strict adherence to the work to make sure that it doesn’t — we don’t — conduct, you know, just bluntly, mad science experiments,” Bhattacharya told The Post in an interview Friday. “No more dangerous gain of function will happen under John’s leadership.”
Focus on taxpayer funding for that research heightened during the COVID-19 pandemic, leading to fierce debates in Congress between Fauci and lawmakers over its role in possibly creating the virus that causes SARS-CoV-2.
As recently as fiscal year 2025, roughly one-third of NIAID’s budget, or more than $2.2 billion, was for biodefense research programs, which now will be run by the Department of War.
“We’re now purely a civilian agency,” Bhattacharya also affirmed. “We’re moving to shift the portfolio so it’s more balanced toward infectious diseases that Americans actually get.”
Powers added that, in his earlier years as a clinician, “I was there when HIV patients were dying. And we made tremendous progress in that area. But right now we’re able to send HIV patients home with one pill once a day. And we’re focusing much more now on implementation research, which means we’re trying to get interventions to people who really need it.”
As a result, Bhattacharya and Powers said they have combed through more than 8,000 research grants to ensure that none of the lab work involved dangerous experiments that would be classified as biodefense.
“Biodefense is research to go find emerging diseases in the middle of nowhere, bring them into labs, make them more transmissible, make them more able to infect humans and then develop sort of hypothetical … poorly tested countermeasures to pretend like we can address them if they if they happen to emerge,” Bhattacharya explained. “We’re out of that business altogether.”
“There were civilian justifications, but those justifications were far-fetched, right? The idea that we could prepare for all pathogens out there — they’re literally in the trillions — and somehow develop countermeasures for all the most important ones by making them more pathogenic,” he added.
Fauci has repeatedly denied in congressional testimony that his agency ever funded such experiments at the Wuhan Institute of Virology, located in the city where COVID-19 emerged in late 2019 — though Bhattacharya and other scientists have disputed this claim or said it is impossible to know what Chinese scientists were researching under the US-funded grant.